PDCD1 and neoplasm: Therefore, therapies targeting tumor immunogenicity and anti-tumor immunity [4] such as antibodies that inhibit checkpoint molecules, i.e. the programmed cell death ligand-1 (PD-L1)/programmed cell death-1 (PD-1) pathway [5] have recently gained attention as a novel therapeutic option in OC [6].